NASDAQ:BRKR - Bruker Stock Price, Price Target & More

Bruker trades on the NASDAQ under the ticker symbol "BRKR."

Bruker declared a quarterly dividend on Tuesday, May 15th. Shareholders of record on Monday, June 4th will be paid a dividend of $0.04 per share on Friday, June 22nd. This represents a $0.16 annualized dividend and a yield of 0.50%. The ex-dividend date of this dividend is Friday, June 1st. View Bruker's Dividend History.

Bruker announced that its Board of Directors has approved a stock repurchase program on Sunday, June 4th 2017, which allows the company to repurchase $225,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's board believes its shares are undervalued.

Bruker (NASDAQ:BRKR) posted its earnings results on Thursday, May, 3rd. The medical research company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.02. The medical research company had revenue of $431.70 million for the quarter, compared to analyst estimates of $419.25 million. Bruker had a return on equity of 27.04% and a net margin of 4.63%. Bruker's revenue was up 12.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.19 EPS. View Bruker's Earnings History.

Bruker is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Bruker.

11 analysts have issued 12 month price targets for Bruker's shares. Their predictions range from $24.00 to $42.00. On average, they anticipate Bruker's stock price to reach $32.80 in the next year. View Analyst Ratings for Bruker.

Some companies that are related to Bruker include Waters (WAT), Mettler-Toledo International (MTD), Bio-Rad Laboratories, Inc. Class A Common Stock (BIO), Bio-Rad Laboratories, Inc. Class B (BIO.B), PerkinElmer (PKI), Integra Lifesciences (IART), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT) and HTG Molecular Diagnostics (HTGM).

Media coverage about BRKR stock has trended somewhat positive this week, according to Accern. The research group identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Bruker earned a daily sentiment score of 0.12 on Accern's scale. They also assigned media stories about the medical research company an impact score of 46.55 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Bruker's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.37%), Russell Investments Group Ltd. (0.95%), Victory Capital Management Inc. (0.88%), Boston Partners (0.83%), Millennium Management LLC (0.71%) and Dimensional Fund Advisors LP (0.61%). Company insiders that own Bruker stock include Frank H Laukien, Ingen Chris Van, Mark Munch, Richard A Packer and Richard Kniss. View Institutional Ownership Trends for Bruker.

BRKR stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Sensato Investors LLC, Victory Capital Management Inc., New York State Common Retirement Fund, Massachusetts Financial Services Co. MA, Hsbc Holdings PLC, Citadel Advisors LLC and Teacher Retirement System of Texas. View Insider Buying and Selling for Bruker.

BRKR stock was acquired by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Allianz Asset Management GmbH, Point72 Asset Management L.P., Old Mutual Global Investors UK Ltd., Carillon Tower Advisers Inc., Great Lakes Advisors LLC, BlackRock Inc. and GSA Capital Partners LLP. Company insiders that have bought Bruker stock in the last two years include Frank H Laukien and Richard A Packer. View Insider Buying and Selling for Bruker.

Shares of BRKR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of BRKR stock can currently be purchased for approximately $31.86.

Bruker has a market capitalization of $5.03 billion and generates $1.77 billion in revenue each year. The medical research company earns $78.60 million in net income (profit) each year or $1.21 on an earnings per share basis. Bruker employs 6,200 workers across the globe.

Bruker's mailing address is 40 Manning Road, Billerica MA, 01821. The medical research company can be reached via phone at 978-663-3660 or via email at [email protected]